|Issue Date||16 Jul 2021 - 20 Jul 2021|
|Issue Size||₹500.0 Cr|
|Market Lot||13 Shares|
|Shares on Offer|
|Subject to Sauda||₹7200-7400|
|Listing Date||29 Jul 2021|
Tatva Chintan Pharma Chem Ltd are a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (“PASC”). Their Company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. (Source: F&S Report) In addition, their Company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. (Source: F&S Report) As a manufacturer of specialty chemicals, they focus on application of their products which form a key ingredient to their customers’ manufacturing and industrial processes. For instance, their SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies. They continuously strive to improve their processes and infrastructure to help reduce their impact on the environment and have accordingly, undertaken various ‘green’ chemistry processes such as electrolysis. Considering the wide application of their products, they serve customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavtheir and fragrances industries. Apart from their customers in India, they also export their products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK.
Their Company is promoted by Chintan Shah, Ajay Patel and Shekhar Somani, who each have over 24 years in the specialty chemicals manufacturing industry and have established strong business relationships with domestic as well as overseas customers. In addition, they are led by a well – qualified and experienced management team, which they believe has demonstrated its ability to manage and grow their operations and has substantial experience in the sectors in which they operate. They believe that the knowledge and experience of their management team provides us with a significant competitive advantage as they seek to grow their business.
Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, and Snehkar Rasiklal Somani are the company promoters.
|Total Assets (In ₹ Millions)||3,148.03||2,489.38||1,875.08|
|Total Revenue (In ₹ Millions)||3,062.92||2,646.22||2,068.01|
|Profit After Tax (PAT) (In ₹ Millions)||522.62||377.89||205.43|
|Date||GMP||Kostak||Subject to Sauda|
|21 Jul 2021||₹760-765||₹350-400||₹7200-7400|
|16 Jul 2021||₹685-690||₹300-350||₹6800-7000|
|14 Jul 2021||₹550-560||₹250-300||₹5000-5200|
|Date & Time||QIB||NII||RII||Total|
|Day 1 - 16 Jul 2021||0.5||1.14||8.24||4.51|
|Day 2 - 19 Jul 2021||1.97||12.21||23.74||15.05|
|Day 3 - 20 Jul 2021||185.23||512.22||35.35||180.36|
Please click the link below to check the IPO allotment status.IPO Allotment Status
Tatva Chintan Pharma Chem Ltd IPO will open on 16 Jul 2021 and close on 20 Jul 2021.
Tatva Chintan Pharma Chem Ltd IPO will list on 29 Jul 2021.
The offer price of Tatva Chintan Pharma Chem Ltd IPO is ₹1073-1083.
The lot size of Tatva Chintan Pharma Chem Ltd IPO is 13.
The Grey Market Premium (GMP) price of Tatva Chintan Pharma Chem Ltd IPO is ₹760-765.
The Kostak price of Tatva Chintan Pharma Chem Ltd IPO is ₹350-400.
The Subject to Sauda price for Tatva Chintan Pharma Chem Ltd IPO is ₹7200-7400.
Please Leave Your Message